Condition: DLBCL · Untreated · MYC Gene Rearrangement · Sponsor: The First Affiliated Hospital with Nanjing Medical University
The prognosis of DLBCL with MYC rearrangement is dismal. Previous study showed that lenalidomide in combination with R-CHOP showed promising therapeutic activity and that R-DA EPOCH was superior compared to R-CHOP regimen in this cohort of patients. The investigators therefore design this phase I/II study to investigate the safety and efficacy of lenalidomide in combination with R-DA EPOCH in patients with untreated MYC-rearranged DLBCL.
This description comes directly from the study's public registry record.
Li Wang, M.D., Ph.D · 86 25 68306034 · lilyw7878@163.com
Wei Xu, M.D., Ph.D · 86 25 68306034 · xuwei10000@hotmail.com
Always discuss trial participation with your own doctor first.
| The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital) | Nanjing, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04432714